WO2024175588 - OLIGONUCLEOTIDES FOR MODULATING SYNAPTOGYRIN-3 EXPRESSION
National phase entry is expected:
Publication Number
WO/2024/175588
Publication Date
29.08.2024
International Application No.
PCT/EP2024/054280
International Filing Date
20.02.2024
Title **
[English]
OLIGONUCLEOTIDES FOR MODULATING SYNAPTOGYRIN-3 EXPRESSION
[French]
OLIGONUCLÉOTIDES POUR MODULER L'EXPRESSION DE LA SYNAPTOGYRINE-3
Applicants **
VIB VZW
Suzanne Tassierstraat 1
9052 Gent, BE
KATHOLIEKE UNIVERSITEIT LEUVEN
K.U.LEUVEN R&D
Waaistraat 6 - bus 5105
3000 Leuven, BE
JAY THERAPEUTICS
Pieter van Reysschootlaan 2 / 104
9051 Gent, BE
Inventors
SANTOS, Ana Rita
c/o VIB vzw
Suzanne Tassierstraat 1
9052 Gent, BE
VERSTREKEN, Patrik
c/o VIB-KU Leuven Center for Brain & Disease Research
Herestraat 49
3000 Leuven, BE
Priority Data
23157708.1
21.02.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2206 | |
| EPO | Filing, Examination | 10567 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 5760 |
Total: 19694 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention relates to regions within the synaptogyrin-3 RNA sequence that are targetable by oligonucleotide inhibitors such as antisense oligonucleotides. In particular, these synaptogyrin-3 inhibitors are provided for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies.[French]
L'invention concerne des régions à l'intérieur de la séquence d'ARN de la synaptogyrine-3 qui peuvent être ciblées par des inhibiteurs d'oligonucléotides tels que des oligonucléotides antisens. En particulier, ces inhibiteurs de synaptogyrine-3 sont fournis pour une utilisation en tant que médicament en général, et pour le traitement ou l'inhibition de la progression de tauopathies ou de symptômes de tauopathies.